BIOMAT Database Logo BIOMAT Database Logo

Irreversible enzyme inhibitors. CXLII. Further studies on active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 5-(p-Aminophenoxypropyl)-2,4,6-triaminopyrimidine bearing a terminal sulfonyl fluoride. 1969

B R Baker, and R B Meyer

UI MeSH Term Description Entries
D007422 Intestines The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE. Intestine
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D005459 Fluorides Inorganic salts of hydrofluoric acid, HF, in which the fluorine atom is in the -1 oxidation state. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Sodium and stannous salts are commonly used in dentifrices. Fluoride
D005493 Folic Acid Antagonists Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) Antifolate,Antifolates,Dihydrofolate Reductase Inhibitor,Folic Acid Antagonist,Dihydrofolate Reductase Inhibitors,Folic Acid Metabolism Inhibitors,Acid Antagonist, Folic,Acid Antagonists, Folic,Antagonist, Folic Acid,Antagonists, Folic Acid,Inhibitor, Dihydrofolate Reductase,Inhibitors, Dihydrofolate Reductase,Reductase Inhibitor, Dihydrofolate,Reductase Inhibitors, Dihydrofolate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001555 Benzene Derivatives Organic compounds derived from BENZENE. Derivatives, Benzene

Related Publications

B R Baker, and R B Meyer
Irreversible enzyme inhibitors. CXXXVII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-(p-aminomethylphenoxymethyl)-2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine bearing a terminal sulfonyl fluoride.
January 1969, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. 138. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-(p-aminomethylphenethyl)-- 2,4-diamino-5-(3,4-dichlorophenyl)pyrimidine with a terminal sulfonyl fluoride.
January 1969, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. 148. Active-site-directed irreversible inhibitors of guanine deaminase derived from 9-phenylguanine bearing a terminal sulfonyl fluoride.
March 1969, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. CXLVII. Candidate active-site-directed irreversible inhibitors of xanthine oxidase derived from 9-(p-acylamidoalkoxyphenyl)guanines bearing a terminal sulfonyl fluoride.
March 1969, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. 185. Active-site-directed irreversible inhibitors of guanine deaminase derived from 9-phenylguanine bearing a terminal sulfonyl fluoride. 2.
September 1971, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. CLV. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 1-[4-(omega-aminoalkoxy)-3-chlorophenyl]-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazines bearing a terminal sulfonyl fluoride.
July 1969, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. CXIV. Proteolytic enzymes. IV. Additional active-site-directed irreversible inhibitors of alpha-chymotrypsin derived from phenoxyacetamides bearing a terminal sulfonyl fluoride.
March 1968, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. CXII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine substituted with a terminal sulfonyl fluoride. II.
January 1968, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. CXV. Proteolytic enzymes. V. Active-site-directed irreversible inhibitors of trypsin derived from p-(phenoxyalkoxy) benzamidines with a terminal sulfonyl fluoride.
March 1968, Journal of medicinal chemistry,
B R Baker, and R B Meyer
Irreversible enzyme inhibitors. CXXV. Active-site-directed irreversible inhibitors of xanthine oxidase derived from arylpurines and pyrazolo[3,4-d]pyrimidines bearing a terminal sulfonyl fluoride.
July 1968, Journal of medicinal chemistry,
Copied contents to your clipboard!